Oncología Médica Traslacional y Terapia Individualizada del Cáncer

Kahan, Z; Gil-Gil, M; Ruiz-Borrego, M; Carrasco, E; Ciruelos, E; Munoz, M; Bermejo, B; Margeli, M; Anton, A; Casas, M; Csoszi, T; Murillo, L; Morales, S; Calvo, L; Lang, I; Alba, E; de la Haba-Rodriguez, J; Ramos, M; Lopez, IA; Gal-Yam, E; Garcia-Palomo, A; Alvarez, E; Gonzalez-Santiago, S; Rodriguez, CA; Servitja, S; Corsaro, M; Rodrigalvarez, G; Zielinski, C; Martin, M.

Original Research Health-related quality of life with palbociclib plus endocrine therapy versus capecitabine in postmenopausal patients with hormone receptor-positive metastatic breast cancer: Patient-reported outcomes in the PEARL study

EUROPEAN JOURNAL OF CANCER. 2021; 156: 70-82 Nº de citas: 12 [doi:10.1016/j.ejca.2021.07.004]

De Laurentiis, M; Borstnar, S; Campone, M; Warner, E; Bofill, JS; Jacot, W; Dent, S; Martin, M; Ring, AL; Cottu, P; Lu, JI; Ciruelos, E; Azim, HA; Chatterjee, S; Zhou, KT; Wu, JW; Menon-Singh, L; Zamagni, C.

Full population results from the core phase of CompLEEment-1, a phase 3b study of ribociclib plus letrozole as first-line therapy for advanced breast cancer in an expanded population

BREAST CANCER RESEARCH AND TREATMENT. 2021; 189(3): 689-699 Nº de citas: 25 [doi:10.1007/s10549-021-06334-0]

Alvarez, YE; Carpeno, JD; Bell, D; Drago, A; Franceschetti, A.

Prevention of chemotherapy-induced nausea and vomiting in the real-world setting in Spain

CLINICAL & TRANSLATIONAL ONCOLOGY. 2021; 23(10): 2155-2162 Nº de citas: 3 [doi:10.1007/s12094-021-02623-8]

Bockorny, B; Macarulla, T; Semenisty, V; Borazanci, E; Feliu, J; Ponz-Sarvise, M; Abad, DG; Oberstein, P; Alistar, A; Munoz, A; Geva, R; Guillen-Ponce, C; Fernandez, MS; Peled, A; Chaney, M; Gliko-Kabir, I; Shemesh-Darvish, L; Ickowicz, D; Sorani, E; Kadosh, S; Vainstein-Haras, A; Hidalgo, M.

Motixafortide and Pembrolizumab Combined to Nanoliposomal Irinotecan, Fluorouracil, and Folinic Acid in Metastatic Pancreatic Cancer: The COMBAT/KEYNOTE-202 Trial

CLINICAL CANCER RESEARCH. 2021; 27(18): 5020-5027 Nº de citas: 55 [doi:10.1158/1078-0432.CCR-21-0929]

Cabezon-Gutierrez, L; Custodio-Cabello, S; Palka-Kotlowska, M; Alonso-Viteri, S; Khosravi-Shahi, P.

Biomarkers of Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer: Beyond PD-L1

CLINICAL LUNG CANCER. 2021; 22(5): 381-389 Nº de citas: 6 [doi:10.1016/j.cllc.2021.03.006]

Garcia-Alfonso, P; Munoz, A; Jimenez-Castro, J; Jimenez-Fonseca, P; Pericay, C; Longo-Munoz, F; Reyna-Fortes, C; Argiles-Martinez, G; Gonzalez-Astorga, B; Gomez-Reina, MJ; Ruiz-Casado, A; Rodriguez-Salas, N; Lopez-Lopez, R; Carmona-Bayonas, A; Conde-Herrero, V; Aranda, E.

Early Clinical Experience with Trifluridine/Tipiracil for Refractory Metastatic Colorectal Cancer: The ROS Study

Cancers. 2021; 13(18): Nº de citas: 8 [doi:10.3390/cancers13184514]

Ramos-Medina, R; Lopez-Tarruella, S; Del Monte-Millan, M; Massarrah, T; Martin, M.

Technical Challenges for CTC Implementation in Breast Cancer

Cancers. 2021; 13(18): Nº de citas: 13 [doi:10.3390/cancers13184619]

Schettini, F; Giuliano, M; Lambertini, M; Bartsch, R; Pinato, DJ; Onesti, CE; Harbeck, N; Luftner, D; Rottey, S; van Dam, PA; Zaman, K; Mustacchi, G; Gligorov, J; Awada, A; Campone, M; Wildiers, H; Gennari, A; Tjan-Heijnen, VCG; Cortes, J; Locci, M; Paris, I; Del Mastro, L; De Placido, S; Martin, M; Jerusalem, G; Venturini, S; Curigliano, G; Generali, D.

Anthracyclines Strike Back: Rediscovering Non-Pegylated Liposomal Doxorubicin in Current Therapeutic Scenarios of Breast Cancer

Cancers. 2021; 13(17): Nº de citas: 10 [doi:10.3390/cancers13174421]

Martinez-Trufero, J; Jurado, JC; Gomez-Mateo, MC; Bernabeu, D; Floria, LJ; Lavernia, J; Sebio, A; del Muro, XG; Alvarez, R; Correa, R; Hernandez-Leon, CN; Marquina, G; Hindi, N; Redondo, A; Martinez, V; Asencio, JM; Mata, C; Morales, CMV; Martin-Broto, J.

Uncommon and peculiar soft tissue sarcomas: Multidisciplinary review and practical recommendations for diagnosis and treatment. Spanish group for Sarcoma research (GEIS - GROUP). Part I

CANCER TREATMENT REVIEWS. 2021; 99: 102259-102259 Nº de citas: 6 [doi:10.1016/j.ctrv.2021.102259]

Martinez-Trufero, J; Jurado, JC; Hernandez-Leon, CN; Correa, R; Asencio, JM; Bernabeu, D; Alvarez, R; Hindi, N; Mata, C; Marquina, G; Martinez, V; Redondo, A; Floria, LJ; Gomez-Mateo, MC; Lavernia, J; Sebio, A; del Muro, XG; Martin-Broto, J; Valverde-Morales, C.

Uncommon and peculiar soft tissue sarcomas: Multidisciplinary review and practical recommendations. Spanish Group for Sarcoma research (GEIS -GROUP). Part II

CANCER TREATMENT REVIEWS. 2021; 99: 102260-102260 Nº de citas: 9 [doi:10.1016/j.ctrv.2021.102260]

Falanga A; Gal GL; Carrier M; Abdel-Razeq H; Ay C; Martin AJM; Rocha ATC; Agnelli G; Elalamy I; Brenner B.

Management of Cancer-Associated Thrombosis: Unmet Needs and Future Perspectives.

Th Open : Companion Journal To Thrombosis And Haemostasis. 2021; 5(3): [doi:10.1055/s-0041-1736037]

Sereno, M; Jimenez-Gordo, AM; Baena-Espinar, J; Aguado, C; Mielgo, X; Pertejo, A; Alvarez-Alvarez, R; Sanchez, A; Lopez, JL; Molina, R; Lopez-Alfonso, A; Hernandez, B; Chiara, LE; Martin, AM; Lopez-Martin, A; Dorta, M; Collazo-Lorduy, A; Casado, E; de Molina, AR; Colmenarejo, G.

A Multicenter Analysis of the Outcome of Cancer Patients with Neutropenia and COVID-19 Optionally Treated with Granulocyte-Colony Stimulating Factor (G-CSF): A Comparative Analysis

Cancers. 2021; 13(16): Nº de citas: 12 [doi:10.3390/cancers13164205]

Mandala, M; Larkin, J; Ascierto, PA; Del Vecchio, M; Gogas, H; Cowey, CL; Arance, A; Dalle, S; Schenker, M; Grob, JJ; Chiarion-Sileni, V; Marquez, I; Butler, MO; Di Giacomo, AM; Lutzky, J; De la Cruz-Merino, L; Atkinson, V; Arenberger, P; Hill, A; Fecher, L; Millward, M; Khushalani, NI; de Pril, V; Lobo, M; Weber, J.

Adjuvant nivolumab for stage III/IV melanoma: evaluation of safety outcomes and association with recurrence-free survival

Journal for ImmunoTherapy of Cancer. 2021; 9(8): Nº de citas: 12 [doi:10.1136/jitc-2021-003188]

Gutierrez-Seijo, A; Garcia-Martinez, E; Barrio-Alonso, C; Pareja-Malagon, M; Acosta-Ocampo, A; Fernandez-Santos, ME; Puig-Kroger, A; Parra-Blanco, V; Mercader, E; Marquez-Rodas, I; Aviles-Izquierdo, JA; Samaniego, R; Sanchez-Mateos, P.

CCL20/TNF/VEGFA Cytokine Secretory Phenotype of Tumor-Associated Macrophages Is a Negative Prognostic Factor in Cutaneous Melanoma

Cancers. 2021; 13(16): Nº de citas: 8 [doi:10.3390/cancers13163943]

Villalvazo, P; Marzal-Alfaro, B; Garcia-Alfonso, P; Revuelta-Herrero, JL; Thomas, F; Lopez-Tarruella, S; Garcia-Gonzalez, X; Calvo, A; Yakoubi, M; Salvador-Martin, S; Lopez-Lopez, F; Aguilar, I; Sanjurjo-Saez, M; Martin, M; Lopez-Fernandez, LA.

DPYD Exome, mRNA Expression and Uracil Levels in Early Severe Toxicity to Fluoropyrimidines: An Extreme Phenotype Approach

Journal Of Personalized Medicine. 2021; 11(8): Nº de citas: 5 [doi:10.3390/jpm11080792]

Slamon, DJ; Neven, P; Chia, S; Jerusalem, G; De Laurentiis, M; Im, S; Petrakova, K; Bianchi, GV; Martin, M; Nusch, A; Sonke, GS; De la Cruz-Merino, L; Beck, JT; Ji, Y; Wang, C; Deore, U; Chakravartty, A; Zarate, JP; Taran, T; Fasching, PA.

Ribociclib plus fulvestrant for postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer in the phase III randomized MONALEESA-3 trial: updated overall survival

ANNALS OF ONCOLOGY. 2021; 32(8): 1015-1024 Nº de citas: 192 [doi:10.1016/j.annonc.2021.05.353]

Polley, MYC; Dickler, MN; Sinnwell, J; Tenner, K; de la Haba, J; Loibl, S; Goetz, MP; Bergh, J; Roberston, J; Couch, F; Ellis, MJ; Martin, M.

A clinical calculator to predict disease outcomes in women with hormone receptor-positive advanced breast cancer treated with first-line endocrine therapy

BREAST CANCER RESEARCH AND TREATMENT. 2021; 189(1): 15-23 Nº de citas: 5 [doi:10.1007/s10549-021-06319-z]

Astorga, BG; Ballabrera, FS; Aguilar, EA; Fernandez, EE; Garcia-Alfonso, P; Flores, EG; Garcia, RV; Montes, AF; Munoz, AML; Salvia, AS.

Patient profiles as an aim to optimize selection in the second line setting: the role of aflibercept

CLINICAL & TRANSLATIONAL ONCOLOGY. 2021; 23(8): 1520-1528 Nº de citas: 4 [doi:10.1007/s12094-021-02568-y]